Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Kiora Pharmaceuticals, with a price target of $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Okunewitch has given his Buy rating due to a combination of factors including Kiora Pharmaceuticals’ strong financial position and promising clinical developments. The company reported an operating loss of $2.5 million for the third quarter of 2025 but maintains a healthy cash reserve of $19.4 million, which is expected to fund operations into late 2027. This financial stability provides a solid foundation for ongoing and future clinical trials.
Additionally, Kiora is advancing two key Phase 2 studies: the ABACUS-2 study for KIO-301 in retinitis pigmentosa and the KLARITY study for KIO-104 in macular edema. KIO-301, a chemical photoswitch designed to restore vision, has shown potential in treating retinal diseases and has been granted orphan drug designation. The company has also secured significant commercial agreements, including partnerships with Laboratories Théa and Senju Pharmaceutical Co., which could provide substantial milestone payments and royalties. These strategic developments and partnerships underpin Okunewitch’s optimistic outlook for Kiora Pharmaceuticals.
Okunewitch covers the Healthcare sector, focusing on stocks such as Lineage Therap, Ocugen, and Citius Oncology. According to TipRanks, Okunewitch has an average return of -0.1% and a 39.92% success rate on recommended stocks.